Jefferies analyst Stephen Volkmann assumes MSC Industrial Direct Co (NYSE:MSM) with a Hold rating and announces Price Target of $84.
Fusion Pharmaceuticals Poised For Leadership In Targeted Cancer Therapies: Oppenheimer
Oppenheimer initiated coverage on Fusion Pharmaceuticals Inc (NASDAQ: FUSN), citing the company's pipeline as among the best in the space with alpha-emitter-based targeted radionuclide therapies (TRTs), with three currently in clinical development.
